University of Michigan researchers have made significant strides in understanding and treating a new, aggressive subtype of prostate cancer linked to the CDK12 gene. They’ve developed a mouse model to study the gene’s impact, discovered how its loss induces DNA damage, and created an innovative oral therapy that targets CDK12 and CDK13, showing promise in […]
Source link